Invitae
Invitae Launches Ciitizen Genome Information Management Platform at JPM
The company believes the platform will expedite its longstanding goal of amassing genomic and other information from patients through their lifespan to fuel discoveries and improve care.
Fulgent Genetics, Bio-Techne Lead Winners as GenomeWeb Index Gains 12 Percent in 2021
While Fulgent's stock price nearly doubled, at the other end of the spectrum, Berkeley Lights saw an 80 percent decline in its share price.
GenomeWeb Index Falls 6 Percent in November as Emergence of Omicron Spooks Markets
The GenomeWeb Index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index last month.
Invitae Sues Natera Over Alleged Infringement of Sequence Assembly Patents
Invitae is seeking damages and other costs, as well as an order enjoining Natera from infringing its '308 and '863 patents, which were granted last month.
The company plans to launch a polygenic risk score, a germline-somatic test platform, and LDT and kitted tests for disease monitoring and therapy selection.
Nov 8, 2021
Invitae Q3 Revenues Increase 66 Percent
Aug 3, 2021
Invitae More Than Doubles Q2 Revenues
May 4, 2021
Invitae Q1 Revenues Increase 61 Percent
Feb 17, 2021
Invitae Q4 2020 Revenues Increase 51 Percent
Feb 1, 2021